DeepVerge has announced its proposed Q1 2022 launch of compact Microtox® PD surveillance units. This upgraded system significantly expands surveillance capabilities into smaller communities and/or facilities/locations where larger groups of people routinely gather, thereby extending the reach of real-time national pandemic response to the local community level.
By accelerating its product evolution beyond just the monitoring large populations through fixed semi-permanent installations, the Group now seeks to capture the technology’s true global potential through the development of smaller, mobile and mass-producible designs that enable Microtox® PD to become a standard part of the home or office utility.
Significantly in this respect, the business model being adopted permits these units to be manufactured and franchised to companies in the developing world in order to speed international access at locally affordable prices.
Recognising that regulatory enforcement and community pressure is likely to demand a sophisticated response from both national and provincial authorities, replacing current manual sampling processes with one capable of delivering instantaneous results combined with predictive analysis from the billions of litres being generated daily, prospective international demand (plus ongoing maintenance) for networked installations of Microtox® PD equipment could become very large indeed.
We would draw your attention to the various disclaimers in the document both at the beginning and at the end of the note. Retail clients (as defined by the rules of the FCA) must not rely on the research document. In particular you should note that the research document is a non-independent marketing communication. The analyst who has prepared the research is aware that TPI provides research to DeepVerge plc. Accordingly the research has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibitions on dealing ahead of its dissemination.
The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.
Copyright © 2021 Turner Pope Investments (TPI) Limited, all rights reserved.
